Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial
Jean‐Jacques Grob(Aix-Marseille Université), Caroline Robert(Institut Gustave Roussy), Keith T. Flaherty(Cancer Research Center), Kamil Drucis(Apple (Israel)), Jeffrey J. Legos(Novartis (United States)), Jacob Schachter, Mayur M. Amonkar(GlaxoSmithKline (United States)), Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Peng Sun(Philips (Finland)), E. Levchenko(Research Medical Center), Axel Hauschild(University Hospital Schleswig-Holstein), Florent Grange(Hôpital Lyon Sud), Georgina V. Long(The University of Sydney), Daniil Stroyakovskiy(Shikoku Cancer Center), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Antoni Ribas(University of California, Los Angeles), Bijoyesh Mookerjee(Novartis (United States)), Paul Nathan(Mount Vernon Hospital), Bogusława Karaszewska(State University of Applied Sciences in Konin), Reinhard Dummer(University Hospital of Zurich), Diane Opatt McDowell(GlaxoSmithKline (United States)), Mikhail Lichinitser(National Cancer Centre Japan), Pascal Wolter(KU Leuven)
Cited by 264
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k